Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 11/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31221823 | 1.00 | LPL (0.43) | LPLLIPGALPLGSK3AGSK3B | |
| SCHEMBL21841087 | 0.85 | CCR1 (0.53) | LPLLIPGALPLPDGFRBKDR | |
| SCHEMBL167417 | 0.78 | ALPL (0.57) | LPLLIPGALPLPDGFRBKDR | |
| SCHEMBL20392548 | 0.78 | CCR1 (0.44) | LPLLIPGIRAK4CCR1CCR5 | |
| SCHEMBL29502745 | 0.78 | CCR1 (0.44) | LPLLIPGIRAK4CCR1CCR5 | |
| SCHEMBL418496 | 0.77 | ALDH1A1 (0.49) | LPLLIPGALPLPDGFRBIRAK4 | |
| SCHEMBL29502750 | 0.77 | ALDH1A1 (0.49) | LPLLIPGALPLPDGFRBIRAK4 | |
| SCHEMBL31513479 | 0.77 | ALDH1A1 (0.49) | LPLLIPGALPLPDGFRBIRAK4 | |
| SCHEMBL30198644 | 0.77 | ALPL (0.42) | LPLLIPGALPLGSK3AGSK3B | |
| SCHEMBL17421093 | 0.77 | ALPL (0.42) | LPLLIPGALPLGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110282063-A1 | METHOD OF PRODUCING A DIAZAFLUORENE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20110282063-A1 | METHOD OF PRODUCING A DIAZAFLUORENE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20080161574-A1 | DIAZAFLUORENE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080161574-A1 | DIAZAFLUORENE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161574-A1 | DIAZAFLUORENE COMPOUND | AFF1, NPFFR1, AFF2 | LPL 4328/4885LIPG 4352/4885ALPL 4431/4885 |
| US-20110282063-A1 | METHOD OF PRODUCING A DIAZAFLUORENE COMPOUND | AFF1, AFF2, AFF4 | LPL 4158/4885LIPG 4442/4885ALPL 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.